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Abstract: The past decade has witnessed enormous progress, and has seen the noncoding RNAs
(ncRNAs) turn from the so-called dark matter RNA to critical functional molecules, influencing most
physiological processes in development and disease contexts. Many ncRNAs interact with each
other and are part of networks that influence the cell transcriptome and proteome and consequently
the outcome of biological processes. The regulatory circuits controlled by ncRNAs have become
increasingly more relevant in cancer. Further understanding of these complex network interactions
and how ncRNAs are regulated, is paving the way for the identification of better therapeutic strategies
in cancer.
Keywords: noncoding RNA; miRNA; lncRNA; circRNA; ncRNA network in cancer; cancer biomarkers;
RNA aided cancer therapy
1. Introduction
A few years after the proposal by Watson and Crick of the central dogma of Molecular Biology,
which suggested the unidirectional flow of genetic information from DNA to coding RNA to protein,
Francis Crick’s “adaptor” hypothesis, suggested the existence of a new RNA class later discovered
to be transfer-RNA (tRNA) that connects messenger RNA (mRNA) and the amino acid sequences
of a protein [1]. Moreover, Walter Gilbert’s “The RNA World” hypothesis that describes a world
made of RNA molecules, the ribozymes, that synthesize themselves, was inspired by the enzymatic
activities of an RNA molecule, a ribonuclease-P (RNP) discovered in prokaryotes—Escherichia coli and
the ribosomal RNA that contains a self-splicing exon discovered in eukaryotes—Tetrahymena [2–4].
Many other discoveries followed, but still most scientific efforts were biased towards coding gene
discovery. Furthermore, at that time there were few methodologies to detect the non-coding portion of
our genome.
Lineage defective-4 (lin-4) and lethal-7 (let-7) were the first microRNAs (miRNA) identified, both
found in Caenorhabditis elegans [5,6]. This was followed by a series of studies dealing with the biogenesis
and function in physiological and pathological conditions of these tiny non-coding RNA oddities. Now
functional non-coding RNAs (ncRNAs) have become the scientific penchants since they constitute
almost 60% of the transcriptional output in humans [7,8]. As the name suggests, the ncRNAs are
not transcribed into proteins but they are remarkable regulators of important molecular processes in
species ranging from Arabidopsis thaliana and Caenorhabditis elegans, to humans [9].
The ncRNA family is generally divided into two main classes: housekeeping ncRNAs and
regulatory RNAs. The housekeeping ncRNAs are involved in essential cellular functions such as
ribosomal RNA (rRNA), transfer RNA (tRNA), small nucleolar RNAs (snoRNAs) and are generally
expressed constitutively. Regulatory ncRNAs are involved in gene regulation and include small
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interfering RNAs (siRNAs), P-element-induced wimpy testes (piwi)-interacting RNAs (piRNAs),
enhancer RNAs (eRNAs), miRNAs and the long-noncoding RNAs (lncRNAs), which include the class
of circular RNAs (circRNAs) [10]. Their length matters when it comes to detecting and distinguishing
them by RNA deep sequencing analysis so their classification is based mainly upon the number of
nucleotides (nt), i.e., 20–22 nt for miRNAs and more than 200 nt for lncRNAs and the circRNAs.
Among the ncRNAs, miRNAs are the most studied, as a post-transcriptional gene regulator
involved in many human phenomena and disease states. According to the last version of miRBase
21 there are a total of 28,645 hairpin precursor miRNAs that produce 35,828 mature miRNAs in
223 species [11]. One gene can be targeted by many miRNAs and one miRNA targets many
genes-through RNA base-pairing and the outcome of this interaction is the post transcriptional
inhibition of the target, or contrarily, can enhance the expression of a gene under specific cellular
conditions and we will examine some paradigms in this review. Proteins may also influence expression
of miRNAs by interfering with their biogenesis. As discussed below, the fact that miRNAs interact
with circRNAs and lncRNAs, makes the scenario even more intriguing.
The discovery of RNA splicing, in 1977 by Phillip A. Sharp and Richard J. Roberts and one year
earlier, of the covalently closed RNA structure of viroids, both became the springboards of discovery of
circRNAs, a class of lncRNAs [12–14]. They were first observed by electron microscopy, 38 years ago,
in the cytoplasm of eukaryotic cells [15]. Later in 1991, while Janice Nigro et al. were characterizing
the tumor suppressor gene Deleted in Colorectal Cancer (DCC) in rats and in humans and in neoplastic
and normal cell types, they identified novel products of splicing, named “scrambled exons” derived
from a trans-splicing between exons that contain complementary sequences in distant regions of their
introns [16]. Subsequently, Capel et al. in 1993 found that Sex determining region Y (SRY) c-DNA
and 5′-Rapid Amplification of cDNA Ends (RACE) clones, isolated from mouse testis had an unusual
circular structure and were abundant, reaching a whopping 90% of all transcripts [17]. In the same
year, another group identified mis-spliced, highly stable, circRNAs of the human proto-oncogene
transcription factor ETS-1 [18]. A few years later, Zaphiropoulos et al., hypothesized that circRNAs
may be formed also through an exon skipping mechanism [19]. In other words, the crossover point of
the covalently closed loop brings together alternate 5′ donor splice sites with the 3′ splice acceptor
sites of non-sequential exons, forming circRNAs. Their length may vary from more than 200 nt to
less than 100 nt. Only in the last few years have we started to understand their biogenesis. The main
reason behind this “neglect” being that they were considered cytoplasmic byproducts of splicing.
Additionally, their identification was missed due to molecular techniques of those days, such as RNA
sequencing analysis, which enriched only poly(A) RNA samples and excluded the “back spliced”
circRNAs because they don’t have poly(A) tail. More recently, thousands of circRNAs in different
species, Drosophila Melanogaster, Caenorabditis elegans, mouse and humans have been identified but
little is known about their biogenesis, function and biological significance [20–22].
Overall, the previously mentioned classes of ncRNAs have critical functions in post-transcriptional
oncogene and tumor suppressor regulation. Also, they may interact or compete with one another.
These interactions are part of the competitive endogenous RNAs (ceRNAs) hypothesis, that includes
pseudogenes which lack coding potential and can include lncRNAs, circRNA that compete for the
same group of miRNA responsive elements (MRE) in the transcriptome and may have implications in
tumorigenesis [23–25].
The review will start with a comparison between miRNA, circRNA and lncRNA biogenesis.
Subsequently, we will focus on the function and regulation of the three classes of ncRNAs in cancer.
In addition, recent insights into how interactions between the various classes of ncRNAs drive or
suppress oncogenesis will be examined. An exploration of these topics is timely, given the flood of new
publications analyzing the role of miRNAs, lncRNAs, and circRNAs in cancer [26,27]. Since, novel
RNA based therapeutics have started to become an intergral part of clinical applications, it becomes
imperative to understand the complexity of ncRNA networks to ensure that such technologies are
applied to cancer treatment [28].
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2. Comparison of the Biogenesis of Noncoding RNAs
The exploration of different steps involved in ncRNAs biogenesis is necessary because the
deregulation of the biogenesis may have implications in oncogenic pathways. Here, we compare the
biogenesis of miRNAs (Figure 1A), circular RNAs (Figure 1B) and lncRNAs (Figure 1C), highlighting
the common aspects, differences as well as some exceptions of noncanonical ncRNAs, that may
follow different pathways during their final maturation. A broader understanding of biogenetic
mechanisms will provide also the right tools to understand ncRNA dependent tumorigenesis better
and consequently devise better therapeutic tools.
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and Drosha bind and cleave the basal stem of pri-miRNAs to liberate the stem-loop pre-miRNA that 
enters the cytoplasm by Exportin 5 (EXP5) where the pre-miRNA loop is cleaved by the RNase III 
Dicer and HIV-1 TAR RNA binding protein (TRBP) to form a mature RNA duplex. One of the two 
strands, the guide strand, is selected by one of the four Argonaute (AGO) proteins and loaded 
together with the passenger strand in the RNA induced silencing complex (RISC). The passenger 
strand is degraded while the guide strand will become the mature miRNA. Non-canonical miRNAs: 
mirtrons: reside in introns at the exon junction site of the pre-mRNA, are spliceosome-dependent and 
have their own processing mechanism, which is independent from microprocessor complex. Mirtrons 
form lariats which are debranched under the action of lariat debranching enzymes (LDE) to fold into 
the pre-miRNA hairpin and proceed through the canonical miRNA pathway maturation. (B): Circular 
RNAs: The canonical spliceosomal machinery produces 3′-5′ backspliced circular pre-mRNA 
transcripts that are composed of exons (exonic circRNAs), or 2′-5′ lariats (intronic RNAs, ciRNAs) and 
exon-intron circRNAs (EIciRNAs). CiRNAs and ElciRNAs remain in the nucleus in contrast to the 
circRNAs, which are transported in the cytoplasm. (C): LncRNAs: Based on their location in the 
genome, lncRNAs may be long intergenic (lincRNAs), between two adjacent genes or intronic or 
within the intron of a protein-coding gene. Antisense lncRNAs as uaRNAs or eRNAs are transcribed 
in an opposite direction from the host gene. Intergenic and intronic lncRNAs are spliced from the pre-
mRNA, through the spliceosomal machinery and can be polyadenylated or not. One of the functions 
of lncRNAs is to decoy miRNAs. 
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first generated in the nucleus, transcribed by polymerase II giving r se to a long, sometimes hundreds
of kilobases 5′ capped and 3′ polyadenylated transcripts. (A): Canonical miRNA: DGCR8 and Drosha
bi and cleave the basal stem of pri-miRNAs to liberate the stem-loop pre-miRNA that enters the
cytoplasm b Exportin 5 ( XP5) where the pre-miRNA loop is cleaved by the RNase III Dicer and HIV-1
TAR RNA binding protein (TRBP) to form a mature RNA duplex. One of the two strands, t e guide
strand, is selected by one of the four Argonaute (AGO) proteins and loaded together with the passenger
strand in the RNA induced silencing complex (RISC). The passenger strand is degraded while the guide
strand will become the mature miRNA. Non-canonical miRNAs: mirtrons: reside in introns at the exon
junction site of the pre-mRNA, are spliceosome-dependent and have their own processing mechanism,
which is independent fro microprocessor complex. Mirtrons form lariats which are debranched
under the action of lariat debranching enzymes (LDE) to fold into the pre-miRNA hairpin and proceed
through the canonical miRNA pathway maturation. (B): Circular RNAs: The canonical spliceosomal
machinery produces 3′-5′ backspliced circular pre-mRNA transcripts that are composed of exons
(exonic circRNAs), or 2′-5′ lariats (intronic RNAs, ciRNAs) and exon-intron circRNAs (EIciRNAs).
CiRNAs and ElciRNAs remain in the nucleus in contrast to the circRNAs, which are transported in the
cytoplasm. (C): LncRNAs: Based on their location in the genome, lncRNAs may be long intergenic
(lincRNAs), between two adjacent genes or intronic or within the intron of a protein-coding gene.
Antisense lncRNAs as uaRNAs or eRNAs are transcribed in an opposite direction from the host gene.
Intergenic and intronic lncRNAs are spliced from the pre-mRNA, through the spliceosomal machinery
and can be polyadenylated or not. One of the functions of lncRNAs is to decoy miRNAs.
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2.1. Similarities and Differences in Biogenesis of ncRNAs
2.1.1. Transcription, Capping and Adenylation
Similarities: Generally, ncRNAs are generated in the nucleus, transcribed by polymerase II (Pol II)
giving rise to a long, usually hundreds of kilobases 5′ capped and 3′ polyadenylated transcript,
the precursor mRNA (pre-mRNA) (Figure 1A–C). But within the lncRNAs the predominant form may
be monoexonic and nonpolyadenylated, particularly in the case of eRNAs and the promoter-associated
upstream antisense lncRNAs (uaRNAs) [29]. The ncRNA genes are interspersed throughout the
genome, and can be intergenic, or intronic.
miRNAs: Intergenic miRNAs (i.e., lin-4 and let-7) are independently transcribed, in contrast
with the intronic miRNAs (i.e., miR-26) that reside in their host gene and are transcribed from the
same promoter as the host gene itself [30,31]. Furthermore, intronic miRNAs need RNA splicing
components to be spliced out from the transcript of their host gene and become mature miRNA.
Whether miRNAs are intergenic or intronic, they can be co-transcribed from a single transcription
unit, named polycistron. A known example is the polycistronic miR-17-92 cluster, which contains six
precursor miRNAs within about 1 kb on chromosome 13 [32].
CircRNAs: They are divided in intronic (ciRNAs), exonic circRNAs and exonic-intronic, (ElciRNAs)
in which exons are circularized with introns (Figure 1B). [33–35]. It is not yet completely clear whether
circRNAs are generated co-transcriptionally (while the introns are being spliced out from the pre-mRNA)
or post-transcriptionally [36]. But experimental evidence in the yeast Saccharomyces cerevisiae and in
the nuclear extract of the human cell line HeLa suggest that circRNAs are generated by an inverse
splicing mechanism of the introns mediated by the spliceosome, giving rise to 3′-5′ back splice
circRNA [37]. The latter may be also formed through an exon skipping mechanism as it has been
demonstrated in cytochrome P-450 2C18 transcript, which is expressed in the human epidermis and in
the Androgen-binding protein (ABP) gene in rat testis [19]. ElciRNAs are also derived from a backsplice
mechanism driven by intron-pairing. The ciRNAs instead, have a 2′-5′ junction and form a lariat RNA [38].
All three classes of circRNAs are derived from the non-polyadenylated fraction of RNA (poly(A)−).
LncRNAs: Based on their location in the genome, lncRNAs are long intergenic (lincRNAs),
between two adjacent genes or intronic, within the intron of a protein-coding gene (Figure 1C).
Generally, a very common characteristic of lncRNAs is the bidirectional or divergent transcription
generated by Pol II, from shared protein-coding gene promoters [39]. Divergent transcription of
lncRNAs is enhanced by the chromatin remodeling complex, SWItch/Sucrose Non-Fermentable
(SWI/SNF) and is inhibited by chromatin assembly factor-1 (CAF1) (further details of lncRNA
biogenesis are reviewed by Quinn et al. [40]). It is also worthy to mention that DICER1, a protein
that aids miRNA biogenesis, along with the transcription factor c-myc, induces lncRNA transcription
from divergently transcribed protein-coding genes [41]. Contrarily, four chromatin remodeling factors
inhibit lncRNA transcription and this inhibition consequently regulates mRNA gene expression [42].
Exceptions within the group of miRNAs: Recently published reports suggest that some intronic
miRNAs, like miR-93, may also have their own promoters [43]. Contrarily, intergenic or exonic
miRNAs, like let-7c, are transcribed from promoters that are in the opposite direction of the gene. Not
only Pol II but also RNA polymerase III (Pol III) can transcribe almost 20% of the human miRNAs
because of the presence of Arthrobacter luteus restriction endonuclease (Alu) transposable elements
upstream of miRNA promoters. A genomic analysis of 42 miRNAs, in almost 100 kilobase pairs (kbp)
long fragment in the human chromosome 19 miRNA cluster (C19MC), had Alu sequences upstream of
their promoters and were transcribed by Pol III [44].
2.1.2. Processing of ncRNAs
Similarities: The pre-mRNA transcript is processed by the spliceosome. While for circRNAs
and lncRNAs, this is the main processing mechanism, it is not the case for every miRNA. There are
non-canonical miRNAs, the mirtrons [45], which are found in introns at the exon junction site of the
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pre-mRNA, and are spliceosome-dependent. In this section, we will also describe some exemptions to
the canonical processing of lncRNAs.
miRNAs: In the nucleus, the microprocessor complex of the RNA-binding protein Di George
Syndrome Critical Region Gene 8 (DGCR8) together with the RNase III enzyme Drosha, binds and
cleaves the basal stem of pri-miRNAs to liberate the stem-loop precursor miRNA (pre-miRNA) of
about 65 nucleotides (nt). Drosha contains a tandem of RNase III domains (RIIIDs) and a double strand
(ds)-RNA binding domain and each domain has a specialized action to cleave accurately at the 11th bp
of the hairpin away from the basal single strand junction of the 5′ strand and 22 bp from the apical
junction. Also, the 3′ strand side of the hairpin is cleaved. These Drosha cleavages create a precise 2nt
overhang from the 3′ side of the stem loop (Figure 1A).
Pri-miRNA, after being processed into a pre-miRNA is exported from the nucleus into the
cytoplasm by Exportin 5 (EXP5) (encoded from XPO5 gene), supported by a Ran-GTP-dependent
mechanism. Furthermore, EXP5 protects pre-miRNA from nucleolytic attack in the nucleus and enables
the interaction between the stem loop and the inner surface. Once in the cytoplasm, the Pre-miRNA
loop is cleaved by the RNase III Dicer and HIV-1 TAR RNA binding protein (TRBP) to form a mature
RNA duplex of almost 22 nucleotides (nt) long with a 3′-end having a two nucleotides overhang.
The 5′ strand of the RNA duplex or rarely the 3′ strand which contains thermodynamically unstable
nucleotides, will be selected as the guide strand, which will become the mature miRNA [46]. This
thermodynamic instability can facilitate the unwinding of the duplex by helicases, such as Gemin3 or
RCK/p54 [47,48]. The guide strand is selected by one of the four Argonaute (AGO) proteins due to
the presence of Uracil (U) at nucleotide position 1 or Adenosine (A) at the 5′ end of the RNA duplex
and loaded together with the passenger strand in the RNA induced silencing complex (RISC) [49,50].
Subsequently, the passenger strand is cleaved and generally degraded, but may also be maintained
or activated [51]. The 22 nt long mature miRNA contains the “seed sequence” (2 to 7 nucleotides) at
the 5′ end for target recognition. Likewise, for the target recognition, complementarity at position
8 and conserved adenosines flanking the seed complementary sites in mRNAs are critical [52,53].
The interaction between the seed sequence and the 3′UTR of the target mRNA impair the translation
and stability of the mRNA transcripts and this interaction occurs not only in the cytoplasm but
occasionally also in the nucleus [54,55].
Exceptions in processing of miRNAs: In a Drosha-deleted human cell line, the canonical miRNA
production was completely abolished except for a few non-canonical miRNAs (mirtrons) that were
Drosha-independent and located in the introns of the mRNA encoding host genes [56]. This indicates
that Drosha processing of the canonical miRNAs is indispensable for their maturation. The pre-miR-451
is the only exception so far of a pre-miRNA that escapes Dicer processing, by binding directly to
Ago2 [57]. miRNAs not associated with RISC are detected in the cytoplasm as miRNA-mRNA duplexes
not bound to Agos. Another exception is that also the 3′-end of a mature miRNA contributes to target
recognition [58–60].
CircRNAs: A chromatin-bound RNA nascent sequencing dataset showed that circRNA and
canonical splicing pre-mRNA antagonize each other and this event is tissue specific and conserved in
Drosophila and humans [20]. The canonical spliceosomal machinery produces backspliced pre-mRNA
using cis regulating mechanisms such as long bordering intronic complementary sequences, the Alu
repeats in humans [61,62]. An example of a human gene locus that contains Alu repeats is the
Homeodomain Interacting Protein Kinase 3 (HIPK3) locus circularization. Trans regulating factors,
are also involved, like the splicing factor Muscleblind (MBL), that promotes circRNA biogenesis in
Drosophila and it is conserved also in mice and in humans [20]. Interestingly, MBL not only binds
to its own exon but also regulates its own circularization. The circularization efficiency seems to be
inversely correlated with the exon length and the intronic complementary sequences which promote
circularization [63].
Importantly, ciRNAs processing depends on consensus RNA sequences next to the 5′ splice site
and branch point that probably makes them resistant to debranching enzymes [64]. They are localized
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in the nucleus and enhance transcription of their parental genes [38]. ElciRNAs are also localized in
the nucleus and interact with small nuclear RNA (snRNA), like U1, that both interact with Pol II at
the promoters of parental genes and activate their transcription [33]. CircRNAs are transported in the
cytoplasm and are very stable because they lack 3′ and 5′ ends and consequently are protected from
any exonuclease activity [35].
LncRNAs: The processing of lncRNAs is similar to the pre-mRNAs processing but there are some
exceptions: Upon Pol II transcription, some of the newly formed lncRNAs, like MALAT1 (metastasis-
associated lung adenocarcinoma transcript 1) and NEAT (nuclear enriched abundant transcript 1),
undergo a particular type of the tRNA-like structure processing at their 3′-ends. The tRNA-like
structure at the 3′-end is cleaved by the ribonuclease P (RNaseP) and generates tRNA-like smallRNA
products and a stable 3’ triple helix containing lncRNAs. The tRNA-like smallRNAs cleaved from
NEAT are unstable whereas those derived from MALAT1 are stable and cytoplasmic [65]. Another
exception is the formation of hybrid molecules such as lnc-pri-miRNA and sno-lncRNAs. It has been
estimated that 17.5% of miRNAs are located in lncRNAs. Examples of these hybrids are: lnc-pri-miR-21
and lnc-pri-miR-122 [66]. The microprocessor complex, that generates the pre-miRNAs, cleaves the
lnc-pri-miRNA molecule and gives rise to an unstable non polyA lncRNA and a pre-miRNA so the
cell can express high levels of miRNA without competing with the transcription of the host gene,
the polyA lncRNA [66]. The sno-RNA related lncRNAs (sno-lncRNAs) are generated from introns
between two sno-RNAs [67]. After splicing sno-lncRNAs can be produced by either box C/D or box
H/ACA snoRNAs and contain snoRNA flanking sequences but deprived of a 3′ poly(A) tail and 5′
cap [68]. Their functional role in cancer is discussed in Section 3.3, dealing with lncRNAs in cancer.
3. Functions of ncRNAs in Cancer
3.1. Deregulation of miRNA Expression in Cancer
3.1.1. miRNA Signatures in Cancer
Many types of cancers are characterized by a specific miRNA signature [69–71]. For example,
miR-155/BIC precursor was found to be highly expressed in pediatric Burkitt lymphoma (BL),
while reduced levels of miR-143 and miR-145 were found in the adenomatous and cancer stages
of colorectal neoplasia [72,73]. Two different miRNA signatures characterize Chronic Lymphocytic
Leukemia (CLL) samples and were associated with the presence or absence of mutations. In addition,
significant differences were observed in miRNA expression in CLL versus normal CD5+ B cells [74].
Furthermore, increased levels of oncomiRs miR-21, miR-155 and the miR-17-92 were found in several
lymphomas and leukemia and conversely the expression of tumor suppressors let-7 and miR-34
is frequently decreased [75–82]. Profiling of 217 mammalian miRNAs differentially expressed in
334 human samples across different types of cancers through a bead-based flow cytometric method
and validated by Northern blots, showed that miRNAs not merely characterize a type of cancer,
but their expression pattern reflects the developmental history of human cancers [70]. Furthermore,
miRNA expression seems higher in normal rather than in tumor tissues. This suggests that the
impaired cellular differentiation associates with a decrease in miRNA expression. miRNA signature in
multiple human cancers reveal the possibility to classify many tumor types and their differentiation
stage based on a specific miRNA expression and their potential use in cancer diagnosis and eventually
also in cancer treatment.
One of the known miRNA signatures is the high expression of miR-155 and miR-21 in
hematological malignancies and especially in lymphomagenesis. In the Eµ-miR155 transgenic
mice, under the control of a VH promoter-Ig heavy chain Eµ enhancer, miR-155 activated the
pre-B stage of differentiation [83]. When its expression was induced, the mice developed leukemia
and high-grade lymphoma. In another study, two mice lymphoma models, miR-21 and miR-155
causes recombination- locus of X-over P1 (Cre-loxP) tetracycline-controlled knock-in mouse, were
developed [76]. These mice upon induction of miR-21 and miR-155, after three months rearing in
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the absence of doxycycline food, developed acute lymphadenopathy and splenomegaly. The same
mice when fed back with doxycycline food, completely recovered from all disease symptoms and the
lymphadenopathy regressed. Anti-miR-21 and anti-miR-155 were placed in nanoparticles composed
of (polylactic-co-glycolicacid) (PLGA) and the Peptide nucleic acid (PNA) with a low pH-induced
transmembrane structure (pHLIP) and were successfully delivered to the mice and reduced the tumor
growth. This study opened a new field of RNA-based therapeutic treatment of lymphoma. In a recent
study, miR-21 encapsulated in tumor-penetrating nanocomplexes (TPN) was successfully delivered
to the tumor site for pancreatic ductal adenocarcinoma (PDAC), on patient-derived-xenograft (PDX)
samples and patient-derived-organoids (PDO) [84]. These findings demonstrate a new paradigm that
paves the way in the use of antimiRs as anticancer drugs.
3.1.2. Cellular miRNAs Interact with Viral Proteins
miRNAs interact with viral proteins in diverse types of virally associated cancers. Interestingly,
about 15–20% of cancers have infectious etiology. Indeed, a broad miRNA profiling of different
viral serotypes suggested that Human Papilloma virus (HPV)-16 and -18 can both upregulate certain
common miRNAs like miR-25, -92a, -93, -106b, both in tumor tissues as well as in, in vitro infected
foreskin derived and vaginal keratinocytes [85]. Furthermore, miR-122 is highly expressed in
hepatocytes, targets the 5′ end of the genomic RNA of Hepatitis C Virus (HCV) and induce the stability
and proliferation of HCV [86]. Many viruses also have evolved viral orthologues of oncogenic cellular
miRNA with identical seed sequences. Oncogenic miR-155 is a case in point, viral orthologues of which,
are found in genomes of KSHV and Marek’s disease virus (MDV) [87]. Epstein-Barr virus (EBV) is
associated with a wide variety of cancers and contributes to cellular transformation in two ways, either
by employing its own miRNA (V-miRNAs) or by altering cellular miRNA expression through virally
encoded latent growth transformation proteins, EBNA2 and LMP1 [88–90]. The virally encoded nuclear
protein, EBNA2, essential for EBV’s transforming potential, was shown to simultaneously increase
miR-21, a noted oncomiR and downregulate miR-146a, which is considered a tumor suppressive
miRNA [91,92]. LMP1 on the other hand, induces miR-155 expression [93]. The same viral protein,
when expressed at high level increases expression of miR-29b to downregulate TCL1 expression [94].
miR-21 is consistently increased by EBV across several different types of tumors like BL and plasma cell
derived malignancies [95,96]. We have recently shown that EBNA2 can increase immune checkpoint
protein PD-L1 by downregulating miR-34a [28]. Cellular miRNA alteration can also be used as a
biomarker of EBV. For example, the expression of specific miRNAs was either increased or decreased
in the context of EBV’s presence in DLBCLs [97]. Overall, virus interaction with host cell miRNA
indicate another level of viral manipulation that helps the propagation and survival of the virus and
the knowledge of this interaction has implications in virally associated tumor therapies.
3.1.3. Defective Biogenesis of miRNAs
Deregulated expression of miRNAs in different cancer types may also reflect a defective
miRNA biogenesis mechanism and maturation. Dicer knock-out mouse embryonic cells failed to
differentiate and low levels of Dicer and Drosha expression are associated with advanced tumor
stage of ovarian cancer and poor response to chemotherapy [98,99]. Contrarily, overexpression of
Dicer was detected in prostate and lung cancer [100,101]. Likewise, high expression of Drosha was
found in cervical squamous cell carcinoma (SCC) which, consequently altered the miRNA profile, and
the cell proliferation, invasion and metastasis were enhanced [102]. A whole exome sequencing of
44 Wilms tumors, identified missense mutations in the RNase IIIB domains of Dicer1 and Drosha [103].
These mutations impaired the expression of let-7 family as well as other tumor suppressor miRNAs,
which derived from the 5′ arm of the miRNA hairpins and this finding could explain one of the main
mechanisms that induce the formation of Wilms tumors. Additionally, the role of Exportin 5 (XPO5) in
tumor progression has been under investigation. Decreased levels of XPO5 protein expression has
been linked with a worst prognosis of renal and esophageal tumors, whereas a better prognosis has
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been seen in multiple myeloma, liver cancer and in non-small-cell lung cancer [104,105]. Recently,
the role of XPO5 has been investigated in liver cancer [106]. Phosphorylation of XPO5 by ERK inhibits
nuclear export of pre-miR-122 in the cytoplasm. Therefore, maturation of miR-122 is impaired and
cannot target septin-9 (SEPT9) oncogene. Expression of this oncogene was found increased and caused
Taxol resistance, a drug used in liver cancer therapy. The discovery of ERK-XPO5 pathway implies
a novel therapeutic strategy towards XPO5 activation. Besides the evidence that miRNA biogenesis
perturbation leads to tumorigenesis, a plethora of other mechanisms are involved as well. Importantly,
it has been shown that 98 of 186 miRNA genes are found in fragile sites and in cancer associated
genomic regions [107].
3.2. circRNAs in Cancer
Thousands of circRNAs, 2000 in human, 1900 in mouse and 700 in Caenorhabditis elegans,
are detected and conserved in different tissues and developmental stages [108]. Furthermore,
25 thousand circRNAs were identified in human fibroblasts, by high-throughput sequencing analysis
of ribosome-depleted and exonuclease treated RNA libraries [109]. Interestingly, they are very stable
in the intracellular milieu exhibiting a half-life of more than 48 h, comparing to that of mRNAs of only
10 h or less and are also resistant to RNA exonucleases [110,111].
Because of the broad expression of circRNAs in various tissues and developmental stages in
diverse species, a computational analysis of circRNAs, miRNAs and mRNAs interactions has been
performed in different diseases, that brought to the development of Circ2Traits database [112]. This
database comprises 1953 predicted human circRNAs datasets, the miR2disease dataset and human
miRNAs associated with 174 different human diseases [113]. The authors of Circ2Traits database
not only identified 49 circRNAs, containing one or more single-nucleotide polymorphism (SNP) in
their Ago-binding sites, but they have also included the genome-wide association study (GWAS) to
create a link between circRNAs associated with disease related SNPs and have predicted the circRNA
interaction with disease associated miRNAs. From their study and Circ2Traits database, a circRNAs
association with gastric and prostate cancer and with other diseases was unraveled.
Another algorithm, circRNADb, includes 32,914 human exonic circRNAs collected from the
literature and gives genomic information about circRNAs as well as internal ribosome entry site (IRES),
open reading frame (ORF) and references [114]. CircBase, provides scripts to identify circRNAs in
sequencing data [115]. The development of such algorithms reveals an increasing interest to explore
interacting networks of circRNAs with miRNAs in disease and particularly in cancer.
A ribosomal-depleted RNA sequencing analysis identified 27,000 circRNAs in six human normal
tissues and seven human cancers tissues [116]. The most abundant circRNA identified in these
tumors was circHIPK3 produced from exon 2 of the HIPK3 gene, that can bind and inhibit nine tumor
suppressor miRNAs, among them miR-124. When circHIPK3 was overexpressed in HEK-293T cells,
the growth inhibitory effect of miR-124 was alleviated. The above findings indicate that circRNAs act
as oncogenes, by sequestering tumor suppressor miRNAs.
A computational analysis of ribo-minus RNA extracted from human umbilical venous endothelial
cells (HUVEC) under hypoxic conditions, identified endothelial circRNAs [117]. One of these circRNAs
is cZNF292. When this circRNA was silenced, the tube formation and spheroid sprouting were reduced
in HUVEC cells, indicating that cZNF292 has proangiogenic activities in vitro. Moreover, no sponging
effect for any miRNA was reported by high-throughput sequencing of RNA isolated by cross-linking
and immunoprecipitation (HITS-CLIP). This is the first study, which links a circRNA with one of the
hallmarks of tumorigenesis, namely hypoxia.
3.3. lncRNA in Cancer
The expression of lncRNAs seems to be more specific than mRNAs in different cell types, tissues in
developmental stages as well as in diseases including cancer [118–121]. As it was previously mentioned
for miRNAs, also lncRNAs may act either as tumor-suppressors or promote carcinogenesis [122].
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The lncRNAs are localized in the nucleus and in cytoplasm. They act in trans or in cis with transcription
factors, miRNAs or other ncRNAs (sno-RNAs) and chromatin DNA. For example, enhancer-associated
lncRNAs (eRNAs) regulate in trans other neighboring genes, in the nucleus, during their transcription
or post transcriptionally. One known example is the regulation of HOX genes (HOTAIR and HOXA),
a group of genes which controls the body orientation, that is, head-to-tail axis of animals, by the
antisense RNA, HOXA transcript at the distal tip, (HOTTIP), which in turn is transcribed by the 5′
end of the HOXA gene. The lincRNA, HOTTIP forms a chromosomal loop, which brings together
HOXA distant genes and activates their transcription [123]. This lincRNA is also known to be highly
expressed across different types of cancers and associated with distal metastasis, high tumor stage and
therefore may serve as a novel biomarker of poor prognosis [124].
A cis acting lncRNA in the nucleus is CCAT1-L (Colorectal Cancer Associated Transcript 1-the
long isoform). It is transcribed upstream of the oncogene MYC enhancer region and promotes
chromosome looping that brings into proximity the super enhancer to the MYC promoter and induces
enhanced transcription of MYC [125]. Furthermore, CCAT1-L specifically interacts with the chromatin
CCCTC-binding factor (CTCF) to maintain and promote the chromatin interaction between the MYC
promoter and its enhancers in CRC cell lines (Figure 2A).
LncRNAs also deregulate the expression of transcriptional regulators through interaction with
the Polycomb Repressive complex 1 and -2 (PRC1,-2) which modifies chromatin histones by promoting
histone H3 lysine 27 trimethylation (H3K27me3) [126,127]. An example is the highly expressed
lincRNA Up-regulated in bladder cancer 1 (linc-UBC1), which is associated with lymph node metastasis
and poor prognosis in bladder cancer (BC) patients. Linc-UBC1 resides in the nucleus where it interacts
with two proteins of the PRC2 complex, Enhancer of Zeste Homolog 2 (EZH2) and Suppressor of
Zeste 12 Homolog (SUZ12). It suppresses in trans, the PRC2 target genes BMP2, KLF4 and HOXA5
leading to increased proliferation of BC human cell lines [128]. Like linc-UBC1, lincRNA HOTAIR also
interacts with PRC2 components SUZ12 and EZH2 to promote tumor progression in breast cancer,
gastrointestinal cancer and hepatocellular carcinoma [129–131].
Another lncRNA that works as molecular scaffold in the nucleus, bringing together regulatory
proteins, is X-inactive specific transcript (XIST). It is required for the transcriptional silencing of
one X-chromosome in female mammals, but its high expression also promotes invasion and cell
proliferation in human glioblastoma stem cells, gastric cancer (GC) tissues and human GC cell
lines [132–134]. Recently, a box H/ACA small nucleolar RNA (snoRNA)-ended lncRNA SLERT
(snoRNA-ended lncRNA enhances pre-ribosomal RNA transcription) has been identified [135].
The presence of sno-RNAs at both ends of SLERT is necessary for the biogenesis and translocation for
SLERT to the nucleolus, where it controls rRNA transcription by Pol I and promotes the pre-rRNA
transcription through interaction with DDX21, a DEAD-box RNA helicase involved in the ribosome
biogenesis. SLERT inhibits the inhibitory effect of DDX1 on Pol I, leading to enhanced transcription
of rRNA, which is associated with uncontrolled transformed mammalian cell proliferation [136].
Deletion of SLERT impairs pre-rRNA transcription and rRNA production, leading to decreased
tumorigenesis [135]. Among the nuclear lncRNAs, MALAT1 (also known as NEAT-2) is evolutionary
highly conserved in mammals. It regulates gene expression and alternative splicing and has been
linked to lung cancer metastasis and to other types of human cancers [137]. As mentioned before,
there are lncRNAs, which reside in the cytoplasm where they exert their regulatory roles. One of these
cytoplasmic lncRNAs is the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)
Interacting LncRNA (NKILA). It binds to NF-κB/IκB complex and inhibits NF-κB activation, known to
be involved in development and progression of human cancer. A negative feedback loop mechanism
explains the initial induction of NKILA by NF-κB followed by NKILA inhibition of NF-κB. Therefore,
NKILA acts as a tumor suppressor against breast cancer progression and metastasis, tongue squamous
cell carcinoma cells and in non-small cell lung cancer (NSCLC) [138–140].
As expected after the discovery of the first lncRNAs in cancer like H19, MALAT1, PCA3, the list
of lncRNAs involved in tumor progression and metastasis is growing and their role as prognostic
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biomarkers and as prominent therapeutic targets in tumor patients is becoming increasingly more
evident [141–143].Int. J. Mol. Sci. 2018, 19, x  10 of 31 
 
 
Figure 2.  Interactions of ncRNAs  in cancer.  (A): LncRNA, CCAT1‐L,  interacts with  the chromatin 
binding  factor, CTCF. CCAT1‐L  is  transcribed  upstream  of  the  oncogene MYC  enhancer  region, 
promotes chromosome looping that brings into proximity the super enhancer to the MYC promoter 
and  induces  enhanced  transcription  of MYC  in  colorectal  cancer.  (B): LncRNAs  (XIST, HOTAIR, 
HOTTIP) compete with  the binding of miRNA  target genes. Each color corresponds  to a  lncRNA‐
oncogene‐miRNA  interaction.  Tumor  suppressor miRNAs  cannot  bind  to  their  target  oncogenes 
because they are sequestered by  lncRNAs. (C): PANDA antisense transcription  is  induced by p53, 
counteracts CDKN1 inhibitory effect on the cell cycle and decoys the transcription factor NF‐YA. The 
latter cannot bind anymore to the promoter of apoptotic activators such as APAF1, BIK, FAS. (TSS: 
transcriptional start site). (D): CDR1 decoys the tumor suppressor miR‐7, which cannot bind to  its 
oncogene  targets. miR‐671 cleaves CDR1 and alleviates miR‐7 decoying. The  latter  is now able  to 
suppress its targets. (E): Circ‐Foxo3 forms a ternary complex with two cell cycle regulatory proteins, 
p21 and CDK2 to block the cell cycle progression. Foxo3 and circ‐Foxo3 in a breast cancer cell line 
decreased cell proliferation and induced extensive cell death due to apoptosis in tumors formed by 
the same cell line in nude mice. (F): Chromosomal translocations of the oncogenes MLL/AF9 in AML 
produce the fusion of the due oncogenes to form fusion (f)‐circM9 and a fusion protein. Both, f‐circM9 
together with the f‐protein induced leukemia in vivo and resistance to chemotherapy. 
Figure 2. Interactions of ncRNAs in cancer. (A): LncRNA, CCAT1-L, interacts with the chromatin
binding factor, CTCF. CCAT1-L is transcribed upstream of the oncogene MYC enhancer region,
promotes chromosome looping that brings into proximity the super enhancer to the MYC promoter
and induces enhanced transcription of MYC in colorectal cancer. (B): LncRNAs (XIST, HOTAIR,
HOTTIP) compete with the binding of miRNA target ge es. Each colo corresponds to a
lncRNA-oncogene-miRNA interaction. Tumor suppressor miRNAs cannot bind to their target
oncogenes because they are sequestered by lncRNAs. (C): PANDA antisense transcription is induced
by p53, counteracts CDKN1 inhibitory effect on the cell cycle and decoys the transcription factor NF-YA.
The latter cannot bind anymore to the promoter of apoptotic activators such as APAF1, BIK, FAS. (TSS:
transcriptional start site). (D): CDR1 decoys the tumor suppressor miR-7, which cannot bind to its
oncogene t rgets. miR-671 cleaves CDR1 and alleviates miR-7 dec yi g. The l tter is now able to
suppress its targets. (E): Circ-Foxo3 forms a t rnary complex wi h two cell cycle regulatory proteins,
p21 and CDK2 to block the cell cycle progression. Foxo3 and circ-Foxo3 in a breast cancer cell line
decreased cell proliferation and induced extensive cell death due to apoptosis in tumors formed by
the same cell line in nude mice. (F): Chromosomal translocations of the oncogenes MLL/AF9 in AML
produce the fusion of the due oncogenes to form fusion (f)-circM9 and a fusion protein. Both, f-circM9
together with the f-protein induced leukemia in vivo and resistance to chemotherapy.
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4. Interaction Networks of ncRNAs in Cancer
4.1. Regulation through Competitive Interactions
4.1.1. Competing lncRNAs
The function of lncRNAs as ceRNAs for miRNAs, transcription factors, RNA-binding proteins
(RBPs), or DNAs and the fact that lncRNAs can be transcribed from pseudogenes, is a subject of
intense ongoing research by several groups and these functions are important in metastasis and in
tumor progression [144,145]. The exemplary interaction between a lncRNA and a miRNA in cancer is
provided by the known lncRNA, XIST. As mentioned earlier, XIST is highly expressed in GC tissues
compared with the normal tissues. Upon knockdown of XIST by antisense oligos in human GC cell
lines, proliferation and apoptosis were also decreased. The mechanism behind the effect of XIST
on cell growth and invasion in GC, involves sequestration of the tumor suppressor miR-497, which
targets the oncogene Metastasis Associated in Colon Cancer 1 (MACC1) (Figure 2B) [134,146]. LncRNA
cancer susceptibility candidate 2 (CASC2) sequesters and suppresses onco-miR-21 responsible for
the malignant progression of human gliomas and on the other hand, miR-21 targets CASC2 [147].
In gastric cancer, HOTAIR is highly expressed, and de-represses the expression of HER2 through
competition for miR-331-3p binding in Ago2-containing ribonucleoprotein complex (Figure 2A) [148].
Another lncRNA, Loc285194, regulated by p53, binds and inhibits miR-211 in RISC complex in colon
carcinoma cell lines [149]. LncRNA growth arrest-specific transcript 5 (GAS5) promoted proliferation,
metastasis and inhibited apoptosis by regulation of miR-301a in esophageal cancer (EC) [150]. It has
been recently reported that HOTTIP functions as an oncogene in small cell lung cancer (SCLC) by
sponging the tumor suppressor miR-216a and consequently increases the expression of BCL-2, a target
of miR-216a. By regulating BCL-2 expression, HOTTIP enhanced chemoresistance of SCLC [151].
However, lncRNAs may not only sequester miRNAs but also transcription factors, as it is described
in Figure 2B [152]. This is the case of the P21 associated ncRNA DNA damage activated (PANDA)
lncRNA, which is transcribed antisense of the transcription start site of the cell cycle gene CDKN1A.
Upon DNA damage by doxorubicin treatment of human fetal ling fibroblasts, PANDA was one of the
five lncRNAs transcribed from CDKN1A. PANDA antisense transcription was found to be exclusively
induced by p53 and this lncRNA sequesters the transcription factor NF-YA, which binds the promoter
of apoptotic activators such as APAF1, BIK, FAS and LRDD (Figure 2C) [153]. Hence, PANDA
counteracts CDKN1 inhibitory effect on the cell cycle and this may have implications in cancerous cell
growth. The importance of untangling the networking mechanisms by which lncRNAs act as ceRNAs
for miRNAs, proteins and DNA in cancer will provide novel and more precise therapeutic targets for
cancer therapy.
4.1.2. Pseudogenes Derived-lncRNAs
Pseudogenes represent duplicative, homologous sequence regions of their parental genes. For a
long time, they were considered “junk DNA” non-coding genes defined also as a relic of evolution,
without any function. Since the discovery in 1977 of the first pseudogene, identified in the 3′-end of its
parental gene, 5S DNA of Xenopus laevis, the field of pseudogenes is finally starting to be important
in malignancy pathways [154]. Pseudogenes may also have their origin through a retrotransposition
of processed mRNAs back into the genome. There are different types of pseudogenes depending on
their origin in the genome and are reviewed elsewhere [155]. Here we will highlight some examples of
pseudogenes derived-lncRNAs in cancer. Pseudogenes act like “endogenous competitors” and affect
miRNA binding on all their gene targets. Poliseno and co-workers identified the first pseudogene
derived-lncRNA in an oncogenic networking, the tumor-suppressor gene phosphatase and tensin
homolog pseudogene1 (PTENpg1) that sequesters numerous PTEN-targeting miRNAs by acting as a
miRNA sponge [156]. They found that expression of PTENpg1 and PTEN was higher in normal human
tissues compared to prostate tumor samples. Later, another study revealed that PTENpg1 transcribes
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two anti-sense RNA isoforms -α and -β (PTENpg1 asRNA-α, and -β) and that they function in an
opposite way. The PTENpg1 asRNA α negatively regulates PTEN expression and the asRNA β is
required for PTENpg1 (sense) to act as a miRNA decoy [157]. Depletion of PTENpg1 asRNA α in
human osteosarcoma cell lines arrested their growth and sensitized cells to the DNA-damaging
agent doxorubicin. The knowledge of this PTENpg1 and other pseudogene ncRNA regulatory
pathways may prove therapeutically relevant in order to control gene expression and simultaneously
provide valuable general information of tumor biology. Another pseudogene derived-lncRNA is
the small ubiquitin-like modifier 1 pseudogene 3, (SUMO1P3). It was found to be upregulated in
human gastric cancer tissues compared with paired-adjacent non-tumorous tissues thus, SUMO1P3
could be useful as a biomarker and a therapeutic target for GC [144]. Additionally, the Double
Homeobox A Pseudogene 8 (DUXAP8) expressed-lncRNA, enhances gastric cancer cell proliferation
and tumorigenesis through silencing PLEKHO1 transcription epigenetically, by binding to EZH2
and SUZ12 [158]. The same pseudogene was highly expressed in colorectal cancer (CRC) and its
expression was positively associated with tumor size, pathological stage and lymphatic metastasis and
was exerting its oncogenic function through epigenetically silencing the tumor suppressors p21 and
PTEN expression [159]. Such observations are critical to our current understanding of gene regulation
and highlight a biological role for pseudogene-expressed lncRNAs in human cells.
4.1.3. Decoying Role of circRNAs
A combination of computational, functional and biochemical analyses revealed that the antisense
Cerebellar Degeneration-Related protein 1 (CDR1as), a known human circRNA, is conserved from
annelids to humans, and contains 74 miR-7 seed matches [108,160]. Additionally, miR-671 cleaves
CDR1as in an Ago2-slicer-dependent manner reducing CDR1 mRNA levels [161]. These studies reveal
the sponging-sequestering effect of circRNAs on miRNAs. The biological significance of circRNAs
decoying effect on miRNAs in cancer was further strengthened by an interesting study which unraveled
that ciRS-7 (CDR1as) sequesters the tumor suppressor miR-7. This miRNA, suppresses EGF receptor
in glioblastoma, IRS-1 and IRS-2, Raf1 and other oncogenes [162]. The ciRS-7/miR-7/miR-671 axis is
quite intriguing and gives new insights of circRNA and miRNAs interaction in cancer. CiRS-7 inhibits
miR-7 repression of its target genes and the miR-671 may liberate miR-7, upon cleavage of ciRS-7
(Figure 2D).
Recently, a small number of circRNAs, which sequester miRNAs have been reported but their
functional role needs further investigation. The SRY circRNA was discovered to harbor complementary
sequences for miRNAs and contains 16 binding sites for miR-138 [17,160]. More recently, another study
identified circRNA-ZNF91 derived from a gene encoding a primate-specific zing-finger protein, ZNF91,
with 39 additional sites for miR-296. CDR1as has 22 binding sites for miR-876-5p/3167 family [163].
In addition, the circular isoform of the coding gene Itchy E3 Ubiquitin Protein Ligase (ITCH), cir-ITCH
functions as a sponge for miR-7, miR-17, and miR-214 in esophageal squamous cell carcinoma (ESCC).
The same miRNAs bind to the 3′UTR of mRNA ITCH. Consequently, cir-ITCH increases the level of
ITCH mRNA and promotes ubiquitination and degradation of phosphorylated Dvl2, thereby inhibiting
the Wnt/β-catenin pathway and this reveals the anti-tumoral property of cir-ITCH [164]. Furthermore,
decreased cir-ITCH level was associated with poor survival of glioma patients, by sponging miR-214
and regulating ITCH-Wnt/β-catenin pathway [165]. Therefore, restoration of cir-ITCH expression
could be a future direction to develop a novel treatment strategy in ESCC and glioma. CircRNAs can
also interact with proteins and an example comes from a study in which the circ-forkhead box O3
(circ-Foxo3) forms a ternary complex with two cell cycle regulatory proteins, p21 and CDK2 and blocks
the cell cycle progression in NIH3T3 cells (Figure 2E) [166]. An analysis of Foxo3 gene revealed that a
pseudogene with high homology to Foxo3 mRNA as well as a circ-Foxo3, was generated from the same
Foxo3 gene [167]. Foxo3 pseudogene (Foxo3P), mRNA and circ-Foxo3 had the same potential binding
sites for 8 miRNAs (three of them are miR-22, miR-138, miR-433) and they could sponge these miRNAs
and increase the tumor suppressor gene Foxo3 translation [168]. Over-expression of Foxo3P, Foxo3
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and circ-Foxo3 in a breast cancer cell line decreased cell proliferation and induced extensive cell death
due to apoptosis in tumors formed by the same cell line in nude mice. Among the aforementioned
Foxo3 molecules, circ-Foxo3 demonstrated to have a more potent miRNA sponging effect and on cell
survival. This may be due to the stability of the circ- Foxo3. As previously mentioned, circRNAs have
a longer half-life than the linear mRNAs and are also resistant to RNA exonucleases. Nevertheless,
the intense investigations on function of circRNAs as a miRNA trap are hampered, mainly because
of the missing loss-of function experiments due to an overlapping of the linear and circular isoforms.
It has been also speculated that the small “free” circRNAs could be carried by exosomes outside of
the cells and this could explain the low abundance of circRNAs [169]. There is ample evidence that
the quantity of circRNAs may exceed their linear isoforms, depending of the cell type and tissue
and may play important role either in progression of cancer or tumor suppression. This may have
therapeutic implications for some types of cancer and although this field is still in its infancy, a future
circRNA-based cancer therapy could become realistic.
4.1.4. Progenitor miRNA
A novel paradigm of a miRNA post-transcriptional mechanism is the discovery of an intermediate
progenitor miRNA described in the biogenesis of the polycistronic onco-miR-17-92 [170]. During
the Emryonic Stem Cell (ESC) differentiation, Gregory and his colleagues noticed that there is an
accumulation of the miR-17-92 cluster, but the levels of miR-92a, one of the members of the cluster, were
stable. They discovered that the reason behind this accumulation was the presence of an inhibitory
domain at the 5′ part of the pri-miR-17-92 that brought it to a higher-order RNA conformation.
Therefore, the microprocessor complex was unable to process the primary transcript into the precursors.
When the 5′ inhibitory domain was cleaved at 9nt before pri-miR-17a loop by the endonuclease
CPSF3 aided by the spliceosome-associated ISY1, enabled the formation of a novel intermediate
structure, named the progenitor miR-17-18a-19a-20a-19a except miR-92a. The latter was processed by
Drosha, creating the 3′-end of pro-miR-17-19a. Importantly, the pro-miR formation was a necessary
intermediate step for the miR-17-92 maturation. The same group proposed the biological relevance of
this additional post-transcriptional step that could explain the opposite anti-tumoral effect of one of
the members of this family, miR-92a, observed in mouse lymphoma [171]. Expression of the miR-17-92
cluster is increased in B cell lymphoma, T cell acute lymphoblastic leukemia (T-ALL) and other tumors.
Interestingly, miR-92a inhibits oncogenic miR-19, which belongs to the same family, and promotes
proteosomal degradation of c-Myc. In contrast, when miR-19 is more expressed, it overcomes the
inhibitory action of miR-92 and promotes tumor progression. Overall, the processing of the cluster
pri-miR-17-92 by CPSF3 and ISY1, gives rise to a pro-miRNA that omits miR-92a from the cluster. This
could explain the antagonism between miRNAs belonging in the same cluster with a high impact on
tumor formation.
5. Disruption of ncRNA Networks in Cancer
5.1. miRNA Editing
Adenosine to inosine (A-to-I) editing catalyzed by adenosine deaminases acting on RNAs
(ADARs) affects miRNA biogenesis and reprograms miRNA targeting [172]. Thousands of hitherto
unknown A-to-I RNA editing sites in human transcripts, in normal tissues and in various cancers have
been identified thanks to the advanced deep sequencing technology and bioinformatics analysis [173].
Editing sites are typically found in introns and in 3′UTRs where inverted Alu repeats form double
stranded RNAs (dsRNAs) [174–176]. Therefore, Alu elements are the substrates of RNA editing.
A-to-I RNA editing by ADAR of pri- and pre-miRNAs may regulate expression and function of their
mature counterparts. ADAR enzymes form a heterodimer complex with Dicer to promote miRNA
processing or inhibit the microprocessor complex cleavage of pri-miRNAs and therefore suppress
miRNA maturation [172,177]. In turn, these enzymes are regulated by CREB and c-Jun transcription
Int. J. Mol. Sci. 2018, 19, 2072 14 of 31
factors. In glioblastomas, editing within miRNA is decreased or lost because the activity of ADAR2
is impaired compared with the normal brain tissue [178]. Upon reconstitution of ADAR2 activity,
miRNA editing was recovered and the expression of onco-miRs and onco-suppressors miRNAs
became balanced as seen in the normal brain tissue. Surprisingly, ADAR2 edited the precursors of
miR-222/221 and miR-21 and decreased the expression of the corresponding oncomiRs in vitro and
in vivo (Figure 3A). In another study, in situ analysis of melanoma samples in microarrays tissue was
performed [179]. This study reported that expression of ADAR1 was frequently reduced during the
metastatic transition. Moreover, knockdown of ADAR1 changed the cell phenotype of 131 cancer
regulators miRNAs and microarray analysis revealed that ADAR1 controls the expression of miRNAs
that target genes associated with these phenotypic changes. Furthermore, overexpression of the
onco-miR, miR-17-5p and a newly identified miR-432 silenced both isoforms of ADAR1 in melanoma
cells. A recent study in melanoma identified that miR-455-5p has two A-to-I editing sites in low
metastatic melanomas and this changed its inhibitory effect on its target, the tumor suppressor gene,
CPEB1 [180]. In other words, A-to-I editing of miR-455-5p changed completely its biological effect
and inhibited melanoma growth and metastasis. In addition, a study revealed that overexpression of
ADAR1 in chordoma, a rare neoplasm of the axial skeleton, accompanied reduced levels of miR-10a and
miR-125a, caused by enhanced pre-miR-10a and pri-miR-125a A-to-I editing [181]. This phenomenon
might contribute to the pathogenesis of chordoma.
In summary, ADAR enzymes seem to have both anti-tumoral or a pro-tumoral effect in different
types of cancer by reducing the expression of onco-miRs or tumor suppressors miRs. These enzymes
thus represent promising targets for tumor therapy.
5.2. Epigenetic Regulation of miRNAs
It is estimated that 40% of the human genes promoter contain Cytosine-phosphodiester
bond-Guanosine (CpG) islands, at the 5′ end of regulatory genes [182]. Many studies have reported
that the 5-carbon of cytosine pyrimidine ring can be methylated and methylation of tumor suppressor
genes may lead to cancer. Since many miRNA promoters are embedded in (CpG) islands of their host
genes involved in neoplastic development, it is reasonable that methylation of these DNA regions of
tumor suppressive miRNAs may lead to the development and progression of cancers. Furthermore,
another epigenetic modification of miRNA promoters is the histone H3 and H4 hypo-acetylation
by Histone Deacetylation (HDAC) enzymes [183]. Evidence that miRNA expression is regulated
through epigenetic modifications of their promoter came from studies of cancerous and healthy
cells treated with DNA-demethylating agents, like 5-Aza-2′-deoxycytidine (5-Aza-CdR) and histone
deacetylase inhibitor, 4-phenylbutyric acid (PBA). It has been reported that the promoter of miR-127
is inserted in CpG islands and it is silenced in primary tumors of prostate, bladder, and colon [184].
After a combinatorial treatment of these cell lines with 5-Aza-CdR and PBA, miR-127 expression was
restored and its target, the proto-oncogene B-cell lymphoma-6 (BCL-6) was repressed (Figure 3B) [185].
Chromatin immunoprecipitation (ChIP) showed that activation of miR-127 expression after treatment
was due to decreased cytosine methylation, H3 acetylation and methylation of H3 at lysine 4 (H3-K4),
around the transcriptional start sites of this gene. Another study has examined the miRNA methylation
profile of human metastatic cancer cells of colon, melanoma and head and neck cancer [186]. Among
other miRNAs, it was found that the CpG islands in the promoter of miR-34b/c, miR-148 and miR-9
were hypermethylated, therefore underexpressed and their target genes expression, c-myc and CDK6
were consequently highly expressed. Surprisingly, it was observed that hypermethylation of these
miRNAs was associated with the metastatic cancer cells in the corresponding lymph nodes. This
finding highlights a promising application of the miRNA methylation profile as a metastatic marker.
Recently, a high-throughput sequencing analysis investigated how chemoresistance of a breast cancer
cell line to adriamycin (ADM) and paclitaxel (PTX) can influence gene expression, methylation status
and miRNA expression in comparison to chemosensitive controls [187]. This study reported that highly
expressed miRNAs in the chemoresistant cells were less methylated around their transcriptional start
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site (TSS) and vice versa. Furthermore, investigators have analyzed genes with Kyoto Encyclopedia Of
Genes and Genomes (KEGG) database, that were regulated by methylation and miRNAs. Seventeen
genes were identified to be associated with methylation and dysregulation of miRNAs and generally
they were involved in the cell motility and EMT pathways. Overall, these studies indicate that
epigenetic mechanisms may control transcription of tumor suppressor miRNAs. Methylation profile
of miRNAs can be engaged as a prognostic marker as well as for metastatic propensity. Moreover,
treatment of tumors with drugs that interrupt this control may have therapeutic implications for
cancer cure.
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expression  increases.  (C): Uridylation of miRNA  and  lncRNA:  the  enzyme TUTase  adds Uridine 
groups at the 3′‐end of pre‐let‐7 and the lncRNA Rmrp. Degradation of oligo‐Uridine tails through 
Figure 3. isruption of ncR Networks in Cancer. (A): miRNA editing: in glioblastoma, AD R2 edit
the precursors of miR-222/221 and miR-21 and decrease expression of the corresponding oncomiRs
i vitro and in vivo, (B): Epigenetic re ulation: Methylation and deacetylation of miR-127 promoter
suppresses expression of the tumor suppressor miRNA. Consequently, BCL6 oncogene expression
incr ases. (C): Uridylation of miRNA and lncRNA: the enzyme TUTase adds ridine groups at the
3′-end of pr -let-7 and the lncRNA Rmrp. Degradation of oligo-Uridine tails through the exonuclease
Dis3L2 unified in the DMD pathway may explain the reduced expression of let-7 and other tumor
suppressor miRNAs as well as lncRNAs deregulation in cancer. (D): 3′UTR regulatory sequences,
ARES: ARES interact with micro-ribonucleoproteins (microRNPs) such as AGO2 as a complex with
other proteins to regulate the stability and translation of mRNAs in response to external or internal
stimuli. miR-369-3 binds ARES, AGO2 and fragile X mental retardation-related protein 1 (FXR1)
complex to induce translation of TNFα, in serum starved HEK293 and HeLa cell lines. When cells start
to proliferate, miR-369-3 inhibits TNFα. (E): RBPs of 3′UTR, Pumilio: Bladder carcinomas selectively
down-regulate miRNAs that cooperate with Pumilio to target E2F3, and multiple tumor cell lines
shorten the 3′-end of the E2F3 mRNA, removing the Pumilio regulatory elements. (F): 3′UTR alterations
SNPs: A somatic SNP in the 3′UTR of the oncogene MDM4 created a new binding site for miR-191. This
miRNA suppressed only the oncogene MDM4-C allelic variant expression and retarded ovarian cancer
progression and the tumor became chemosensitive. (G): LncRNA modifications: (1) Methylation: tumor
suppressor, lncRNA MEG3, has binding sites for onco-miR-9, so that it does not bind its targets, FOXO1
and E-cadherin, in ESCC human cell lines. Promoter of lncRNA MEG3 is usually methylated in ESCC
and cannot sequester miR-9 and this induces to proliferation of cancer cells. (2) SNPs: lncRNA PTENP1
polymorphism rs7853346 in GC, change the local folding structure of lncRNAPTENP1. The latter is not
able to exert its decoying effect on miR-106b and miR-93, with a consequent reduction of the tumor
suppressor PTEN gene expression.
5.3. Uridylation of the 3′-End of ncRNAs
Several studies in plants and animal models indicate that uridylation regulates ncRNAs whereas
longer mRNAs are degraded after addition of uridines [188,189]. The only known substrate in
the nucleus of uridylation is the small nucleolar (snoRNA) RNA U6, operated by the U6 Terminal
Uridylyl Transferase (TUTase), an essential enzyme for cell survival in mammals [190]. The addition
of four Uridine residues in the 3′-end of U6 is essential for its splicing function. In the cytoplasm,
polyuridylation occurs on polyadenylated and non-polyadenylated RNA such as miRNAs and has
been shown to regulate miRNA biogenesis and activity [191].
Deep sequencing analysis with strand specific RNA linker ligation to identify and examine the
3′-ends of small RNAs in human embryonic stem cells, suggested that the largest non-template
modification was uridylation, especially in mature miRNAs, such as miR-302-367 cluster [192].
A further high-throughput sequencing analysis specifically for miRNA precursors was performed to
better understand the mechanism and function of oligo-uridylation in the 3′-end of miRNAs [193].
Many pre-microRNAs were found to be uridylated and this modification was increased in
differentiated adult mouse tissues. Among pre-miRNAs, pre-let-7 family was identified. It is known
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from previous studies that let-7 precursor is uridylated at the 3′-end by the uridylyl transferase,
TUTase4 (TUT4) (Figure 3C) [194]. In this mechanism, Lin28 binds the conserved sequence motif
GGAG in the terminal loop of pre-let-7 and triggers the Terminal Uridylyl Transferases 4 and 7
(TUT4/7). This finally inhibits let-7 maturation in embryonic stem cells affecting their maintenance.
Dis3L2, an RNase II/3′-5′exonuclease, which is the catalytic subunit of the RNA exosome recognizes
and degrades the oligo-uridylated pre-let-7 [195,196]. This enzyme is mutated in the Perlman syndrome
and in Wilms tumors and its role in tumorigenesis is only recently unraveled after the discovery of the
Dis3L2-Mediated Decay (DMD) pathway [197,198]. An analysis of Dis3L2 targets in mouse embryonic
stem cells after an RNA immunoprecipitation assay identified lncRNAs and pseudogenes in DMD
pathway. A series of in vitro Dis3L2 loss-of- function experiments helped to determine that some of
the lncRNAs were 3′ uridylated and as expected they were accumulated in the cytoplasm (Figure 3C).
Deep sequencing of the 3′-ends particularly of the RNA Component of Mitochondrial RNA Processing
Endoribonuclease lncRNA (Rmrp), identified that the uridine tail was added to those which contained
CAC nucleotides after the 3′-end and thereby were degraded by Dis3L2. DMD pathway is a guardian
sentinel of the aberrant oligo-uridylated RNA species that should be degraded especially when these
RNAs are cancer-related. The ncRNAs and the subsequent degradation of oligo-Uridine tails through
Dis3L2 enzyme unified in the DMD pathway may explain the reduced expression of let-7 and other
tumor suppressor miRNAs as well as lncRNAs deregulated in cancer [199].
5.4. Phosphorylation of the 5′ End of miRNAs
The mere presence and detection of a miRNA in the cytoplasm does not imply its activity. Indeed,
a miRNA is active when it is able to repress its target genes unless its activity is compromised by
various alterations, as described earlier.
A novel paradigm of a miRNA modification that enhances its activation has been recently
discovered and it is the phosphorylation of the 5′ end in the mature tumor suppressor miR-34 [200].
This miRNA is usually methylated thereby under-expressed in human malignancies or because miR-34
gene locus, 1p36, is frequently deleted in human tumors [201]. Although in some instances, it can
also be present abundantly in human cancer cell lines [202]. It is also known that p53 binds to the
promoter of miR-34 and enhances the transcription thereof, especially when a DNA damage external
signal is triggered. Furthermore, many miRNAs when knocked down, do not influence important
biological functions but might respond to external stimulus, such as irradiation. In fact, in this
study a pool of mature and inactive miR-34 was detected in cancer cell lines. But when the same
cells underwent ionizing irradiation (IR) to induce DNA damage, this pool became activated. The
activation was through the human RNA 5′-kinase (hClp1) and Ataxia telangiectasia (ATM)-dependent
5′ phosphorylation of the mature miR-34. Interestingly, 5′ phosphorylated miR-34a suppressed its
targets genes, Cyclin Dependent Kinase 4 (CDK4) and B-cell Lymphoma 2 (BCL2). This surprising
finding may explain why regardless of a high expression of miRNAs, sometimes they might not be
functionally active. More importantly, this innovative modification could be further explored in other
tumor suppressor miRNAs as a rapid cellular defense to external stimuli. This study provides an
interesting perspective for a cancer therapy based on the activation of the existing inactive tumor
suppressor pool inside the cytoplasm rather than injecting miRNAs intravenously in human patients.
5.5. Alterations and Regulatory Sequences within 3′UTRs
The 3′ untranslated regions (3′UTRs) of mRNAs is defined as the sequence between the STOP
codon and the poly(A) tail. It is important for their transportation into the cytoplasm, the stability
and translational efficiency of mRNAs. These regions are targeted by miRNAs, therefore length
variations of 3′UTRs of many genes affect their regulation by miRNAs. These alterations derive from
the alternative polyadenylation mechanism (APA) present in more than 70% of the mammalian genes.
This leads to formation of isoforms with multiple 3′UTRs derived from a single gene. The length of a
3′UTR is dictated by alternative splicing and more frequently by the cleavage and polyadenylation
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of the pre-mRNA at defined sequences, 10–30 nt after the canonical sequence AAUAAA or its
variants known as polyadenylation sites (PAS) [203,204]. Moreover, short 3′UTRs are more stable
therefore more abundant because they are no longer recognized by miRNAs to suppress the translation.
This phenomenon is frequently observed in actively proliferating cells and in cancer [205].
Equally important and well connected to APA mechanism is the presence of regulatory sequences
within 3′UTRs. An example is the ubiquity of Adenosine-Uracil elements (ARES), which are conserved
sequences within mRNA 3′UTRs. ARES interact with micro-ribonucleoproteins (microRNPs) such
as AGO2 in complex with other proteins to regulate the stability and translation of mRNAs in
response to external or internal stimuli [206]. A seminal observation that miRNAs may induce mRNA
translation demonstrated that miR-369-3, interact with AGO2 and fragile X mental retardation-related
protein 1 (FXR1) complex to induce translation of TNFα, in serum starved HEK293 and HeLa cell lines
(Figure 3D). Therefore, upon cell cycle arrest, the interaction between the seed sequence of the miRNA
within the minimal TNFα ARE 3′UTR induces TNFα translation but in proliferating cells, miRNA had
exactly the opposite inhibitory effect [207]. Similarly, let-7 enhanced translation of its target mRNA in
quiescent cells and repressed it when the cells were proliferating.
In another study, a translational control element (TCE) within the Kruppel Like Factor (KLF4)
3′UTR interacted with miR-206 and miR-344-1 to promote or inhibit KLF4 expression respectively,
in proliferating normal human mammary epithelial cells [208]. miR-206 induced translation of KLF4
to enhance the malignant phenotype in human mammary epithelial cells.
Overall, trans-factors such as RNA binding proteins (RBP) and miRNAs act to contend or
cooperate with each other in order to regulate cis-regulatory sequences within mRNAs involved
in cancer [209–211]. Another example of this mechanism includes the RBP Human antigen R (HuR),
a member of the human embryonic lethal abnormal visual (Elav) gene family that stabilizes and
regulates translation of mRNA [212,213]. Recently, a dissecting study of the KRAS 3′UTR oncogene
in HeLa cells identified two 49-nt cis-regulatory sequences and miR-185 was able to bind one, while
the other contained a stabilizing element [210]. Furthermore, knocking down of HuR and Dicer
has increased mRNA and protein levels of KRAS. These results indicate that miRNA and HuR
cooperatively bind the same sequence in the 3′UTR of this oncogene and repress its expression.
Moreover, in the same repressive 49-nt sequence there was a single nucleotide polymorphism (SNP) at
the first nucleotide of the predicted miR-185 target site but its role in the tumorigenesis has yet to be
determined in the above context.
Other RBP reported to be involved in human malignancies, is the human Pumilio protein complex,
which upon binding to cis-regulatory sequences within 3′UTRs, induces a conformational change
in the RNA structure and regulates miRNAs activity towards their target genes [214–216]. Bladder
carcinomas selectively down-regulate miR-503 and miR-125b that cooperate with Pumilio to target
E2F3, and multiple tumor cell lines shorten the 3′-end of the E2F3 mRNA, removing the Pumilio
regulatory elements (Figure 3E) [217]. These observations indicate one of the ways how oncogenes
escape the inhibitory effect of tumor suppressor miRNAs. Among the RBPs that regulate miRNA
targeting on mRNAs in the nucleoplasm and cytoplasm, the Splicing factor proline/glutamine-rich
protein (Sfpq) promotes let-7a-mediated degradation on Lin28 3′UTR mRNA through a nuclear
mechanism in human and mice cell lines [54]. The multitude of actions of many other RBP proteins
known to interfere with binding sites within 3′UTRs of genes involved in tumorigenesis and influence
miRNAs seed sequences still need to be explored [218]. Altogether, interactive networks between
3′UTRs, RBP, miRNAs and specific cellular conditions entail a new window of opportunity for cancer
therapy, by repressing or enhancing important interactions within these networks.
As mentioned above, in the general view of 3′UTR aberrations are the single nucleotide
polymorphism (SNPs) that interrupt cis-acting regulatory elements embedded in the 3′UTR as well as
chromosomal translocations that involve the 3′UTR resulting in the loss of miRNA complementary
sites [219].
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The SNPs are involved in many types of cancers and they occur frequently in the human genome,
at about every hundred base pairs (bp) [220]. Interestingly, SNPs are usually silent mutations of a single
nucleotide, which do not alter the amino acid sequence, however, there are nonsynonymous SNPs that
change the amino acid sequence to create a new protein and gene function. The silent polymorphisms
may reside in non-coding genomic regions like miRNAs and 3′UTRs. When polymorphisms fall
into an important region of the miRNA seed sequence the regulation of its target genes will be
abrogated. Since the first study of a wide-genome analysis DNA sequencing of tumor tissues
whereby 12 miRNA-binding SNPs were identified to be associated with human cancer, many more
studies have emerged [221]. For example, in lung cancer, a germline SNP in the 3′UTR of KRAS
proto-oncogene abrogated the binding site of let-7, thus increasing KRAS protein levels and promoted
tumor progression [222]. Moreover, a somatic SNP was found in the 3′UTR of the oncogene Mouse
Double Minute 4 (MDM4) known to decrease p53 tumor suppressor function, which created a new
binding site for miR-191. This miRNA suppressed only the MDM4-C allelic variant expression
and retarded ovarian cancer progression and the tumor became chemosensitive (Figure 3F) [223].
A wide-genome analysis for SNPs associated with breast cancer within 3′UTRs that modify miRNA
binding sites identified two SNPs, one in the BRCA1 3′UTR that created a binding site for the miR-638
and decreased the levels of BRCA1 protein in breast cancer cells whereas the other was in the TGFBR1
3′UTR and created a binding site for miR-268 [224]. These findings show that SNPs may turn out to be
valuable as cancer biomarkers which affect prognosis as well as response to therapy.
5.6. Genetic Alterations
Since tumorigenesis involves genomic alterations, such as chromosomal translocations that may
influence or produce proto-oncogenes and onco-suppressors as well as “fusion genes”, a recent
pioneering study investigated the impact these genomic alterations may have on non-coding
RNAs and specifically on circRNAs [225]. One example of fusion genes is the breakpoint cluster
region protein-Abelson murine leukemia viral oncogene (BCR-ABL) gene on chromosome 22 or
Philadelphia chromosome, discovered in leukemia patients. The investigators showed that upon
chromosomal translocation, the two genes bring complementary repetitive intronic sequences (Alu),
which generally favors back-splicing events to generate aberrant circRNAs, called fusion (f)-circRNAs.
They demonstrated that many recurrent chromosomal translocations, of PML/RARα observed in Acute
Promyelocytic Leukemia (APL), MLL/AF9 in Acute Myeloid Leukemia (AML), EWSR1/FLI1 in Ewing
Sarcoma and EML4/ALK1 associated with lung cancer could form f-circRNAs [226,227]. Interestingly,
the f-circM9 derived from MLL/AF9 fusion and f-circPR (derived from PML/RARα fusion), enhance
proliferation of leukemia cells in vitro (Figure 2F). But the f-circRNAs failed to induce leukemia in
mice. When both the f-circRNA and the fusion protein (f-protein) were overexpressed in leukemia
cells and introduced in mice, they enhanced leukemia progression and resistance to chemotherapy.
The intriguing role of circRNAs in tumorigenesis has only started to be uncovered and the number
of circRNAs involved in cancer is progressively increasing. Computational identification of these
remarkable ncRNAs as well as an accurate estimation of their abundance and function in every type of
cancer will aid potential therapeutic approaches based on them.
5.7. lncRNA Modifications in Cancer
Dysregulated lncRNAs due to methylation or mutation in single nucleotides may occur in cancer.
For example, the reason behind the low expression of lncRNA LOC100130476 in the pathogenesis of
esophageal squamous cell carcinoma (ESCC) has been investigated in 123 ESCC patients comparing
with the normal tissues. Low expression was due to hypermethylation of the CpG sites in exon 1
closing to the transcription start site of LOC100130476 [228]. The ESCC patients with low expression
or hypermethylation of this lncRNA had a poor prognosis. The aberrant hypermethylation within
the three CpG islands regions around the transcription start site of another lncRNA CTC-276P9 was
identified in esophageal cancer cells and ESCC tissues and was also related with poor survival of
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ESCC patients [229]. In another study, the promoter region of maternally expressed gene 3 (MEG3)
lncRNA was methylated in ESCC. Interestingly, this lncRNA has ceRNA functions. It sequesters the
onco-miR-9 so that it does not target FOXO1 and E-cadherin in ESCC human cell lines, eventually
leading to inhibition of tumor cell proliferation (Figure 3G1) [230]. The above examples identify three
lncRNA as prognostic biomarkers and therapeutic targets for ESCC patients. Three lncRNA PTENP1
tagSNPs, namely, rs7853346 C>G, rs865005 C>T, and rs10971638 G>A were genotyped in 768 GC
patients and 768 cancer-free controls in a Chinese population [231]. Those patients with rs7853346
G allele had significantly reduced risk of GC, compared with those carrying C allele and was more
obvious in older subjects (≥60 years), nonsmokers, nondrinkers, and subjects without family history
of GC. Through bioinformatics analyses, it was found that rs7853346 might change the local folding
structure of lncPTENP1 abolishing its sponging effect on miR-106b and miR-93 with a consequent
reduction of the tumor suppressor PTEN gene expression (Figure 3G2). These data suggest that GC
susceptibility can be predicted by lncRNA PTENP1 polymorphism rs7853346 [231]. In another study it
was found that the lncRNA H19 SNPs may contribute to susceptibility to GC resulting in gain and loss
of function of miRNA-lncRNA interactions [232].
6. Perspectives
As the so-called dark matter ncRNAs gets more and more elucidated, we have started to uncover
some fascinating concepts and paradigms showing how they interact with each other, both in normal
and diseased circumstances. The role of miRNAs is definitely the most studied among ncRNAs,
mainly because they have the advantage of having been discovered earlier than their longer kins. In
order to broaden the knowledge of how lncRNAs contribute to cancer development, besides studying
their networking ability to act as ceRNA for miRNA, proteins and DNA, the development of suitable
animal model systems will be critical. Revelation of pseudogene-derived lncRNAs is an exciting
new development and how these lncRNAs interact with miRNAs will provide novel biomarkers and
prognostic tools for cancer. The relatively younger protagonists, namely circRNAs which act as miRNA
traps and the fusion circRNAs generated during chromosomal translocation further emphasize how the
complex network of ncRNAs is perturbed in cancer. A better individual and collective understanding
of the members of this nefarious nexus will set the stage for RNA aided cancer therapy.
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